GSK's VC unit SR One has new chief

There's some new blood at the helm of London-based drug giant GlaxoSmithKline's venture group. Jens Eckstein, previously a venture partner and entrepreneur-in-residence at TVM Capital, has jumped aboard as president of SR One. He takes over for biotech venture capitalist Christoph Westphal, who had been wearing multiple hats. Westphal ran the show at SR One while serving as a partner of his own VC group, Longwood Founders Fund, which has funding support from GSK, Genzyme and other sources. Eckstein, a biochemist by training, was a general partner focused on early stage life sciences investments before his role changed to venture partner and EIR earlier this year. Release

Suggested Articles

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research.

In a 7-2 vote, an FDA panel backed Aimmune’s peanut allergy treatment for approval. It desensitizes patients with increasing doses of peanut protein.

In a phase 1 trial of Atara's T-cell therapy for MS, patients who received the highest of the two doses reported showed an improvement in symptoms.